Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A target product profile (TPP) guides the development of new pediatric Chagas disease treatments. This profile outlines essential characteristics for effective drug formulations for children infected with Trypanosoma cruzi.
Area Of Science
- Neglected tropical diseases
- Pediatric pharmacology
- Parasitic infections
Background
- Chagas disease, caused by Trypanosoma cruzi, is a serious neglected tropical disease often acquired in childhood.
- Untreated infections can lead to severe cardiac complications and early mortality.
- Limited pediatric formulations have historically hindered effective treatment in children.
Purpose Of The Study
- To establish a Target Product Profile (TPP) for pediatric drug formulations for Chagas disease.
- To guide the development of new, effective, and age-appropriate treatments for children.
- To address the need for improved therapeutic options for Trypanosoma cruzi infection in pediatric populations.
Main Methods
- Literature review of existing pediatric Chagas disease treatments.
- Convening a consensus-based working group of experts in the field.
- Defining essential and ideal requirements for the TPP based on performance and use characteristics.
Main Results
- The TPP encompasses 15 attributes for new drug formulations targeting children up to 18 years.
- Essential indications include acute/congenital and chronic Trypanosoma cruzi infection.
- Ideal indications extend to specific populations and infection types, emphasizing age-appropriate formulation, palatability, and ease of administration.
Conclusions
- The developed TPP offers crucial guidance for creating new drug formulations for pediatric Chagas disease.
- It specifies essential and ideal characteristics necessary for effective treatment in children.
- This profile supports the advancement of pediatric therapeutic options for Trypanosoma cruzi infections.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...